Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028

June 2023 | 740 pages | ID: G6C52EE4D45EEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028 Report Highlights:

• Global Breast Cancer Immunotherapy Market Opportunity > USD 60 Billion By 2028
• Global Market & Regional Market Trends
• Global Market Forecast Till 2028
• Approved Drugs Yearly & Quarterly Sales Insight 2019 – 2023
• Approved Drugs Global & Regional Sales Insight 2019 – 2023
• Approved Drug Pricing & Dosage Analysis
• Comprehensive Insight On 250 Drugs In Clinical Trials By Company, Country, Patent
• Clinical Insight On More Than 20 Approved Biosimilars & Branded Drugs
• Competitive Landscape

With scientific progress, pharmaceutical research and development activities have led to the generation of novel and innovative therapies, which are creating a new era for cancer treatment. Immunotherapy is one such approach that has been around for years but only recently, researchers have been actively working on determing its therapeutic potential. Continuous innovation in breast cancer treatment has enabled the breakthrough of several novel immunotherapeutic approaches.

While conventional methods like surgery and chemotherapy have become primary therapeutic options, their long lasting side effects and growing possibility of developing drug resistance and cancer recurrence have called for the development of more effective treatment options. The introduction of immunotherapy, particularly immune checkpoint inhibitors has transformed the treatment for breast cancer, with immunotherapy being effective even in aggressive forms of breast cancer such as triple negative breast cancer.

The growing demand for therapies having minimal adverse effects, improved drug development, increasing cancer incidence and growing adoption to cancer immunotherapy above other available treatment options are key factors which are propelling the growth of the market. Moreover, with approved immunotherapeutic drugs for breast cancer showing robust sales has been another factor which has resulted in growing number of investments in the market.

Keytruda, developed by Merck has been a “blockbuster” immune checkpoint inhibitor approved for breast cancer. Since, its approval, the immunotherapy drug has only witnessed an exponential growth in its annual sales. Moreover, Merck has also played strategically by introducing several combinations of this blockbuster immunotherapy drug with other treatments, creating a wider range of patient population choosing Keytruda over other methods.

It can be said that immune checkpoint inhibitors have been a vital factor that have resulted the growing market of breast cancer immunotherapy. Following Keytruda, several companies have launched their respective immune checkpoint blockers; however, none has had higher success than Keytruda. The improved understanding about immune evasion by cancer cells and the development of antibodies towards tumor associated antigens have led to the enhanced growth observed in immunotherapy for breast cancer.

Additionally, moving beyond immune checkpoint inhibitors, the market of breast cancer immunotherapy is also witnessing a rise in novel treatment approaches. For instance, several pharmaceutical companies have been transforming different novel immunotherapy options for breast cancer treatment, like bispecific antibodies, oncolytic viruses, cancer vaccines, tumor infiltrating lymphocyte therapy and cell and gene therapies. While some of these methods have has huge impact of hematological malignancies, pharmaceutical companies are not investigating their potential therapeutic application for breast treatment.

For the last two decades, monoclonal antibody based therapies have brought in incredible changes in the field of breast cancer treatment, however, over time with the surge of bispecific antibodies, several clinical trials are evaluating their therapeutic potential in breast cancer. The possibility of engaging the immune system while simultaneously targeting tumor specific antigens is expected to generate a more robust immune response. For the future, it is easily predictable that bispecific antibodies will change the treatment landscape for breast cancer immunotherapy.

Another immunotherapeutic approach that is currently gardening significant attention for researchers all over the world is tumor infiltrating lymphocyte (TIL) therapy. Studies have shown that TILs are one of the strongest biomarkers present specifically for triple negative breast cancer patients and could also possibly be factors resulting in positive prognosis of the disease. Hence, as we move towards immunotherapy for breast cancer, evaluation of tumor infiltrating lymphocytes could be a very affordable ad well as valuable approach that can be combined with already existing or newly emerging techniques.

Additionally, the involvement of academic institutions and research centers has also played a significant role in transforming the global market of breast cancer immunotherapy. Collaborating between pharmaceutical companies as well as academic instructions has been driving innovation in the field, creating a robust portfolio of immunotherapy candidates in the market. With increasing breast cancer incidence, there also grows a significant need to develop more effective therapeutic approaches and the onset of immunotherapy has offered a promising future.

Our report provides an in depth analysis about the commercially available breast cancer immunotherapy drugs. The report describes the current market of breast cancer immunotherapy with insights on the market growth while also highlighting impact on regional sales, pricing, dosage and patent expiration dates. Moreover, the report also includes new trends in the breast cancer immunotherapy market, information about company collaborations, partnerships.

Contents

1. NEED FOR BREAST CANCER IMMUNOTHERAPY?

1.1 Overview
1.2 Breast Cancer Immunotherapy Mechanism Of Action
1.3 Potential Breast Cancer Biomarkers

2. GLOBAL BREAST CANCER IMMUNOTHERAPY MARKET OVERVIEW

2.1 Breast Cancer Global Market Insight: Yearly & Quarterly Sales (2019 – 2023)
2.2 Global Breast Cancer Immunotherapy Market Future Outlook (2023 – 2028)

3. GLOBAL BREAST CANCER IMMUNOTHERAPY TREND ANALYSIS

3.1 US
3.2 UK
3.3 Canada
3.4 Europe
  3.4.1 Germany
  3.4.2 France
  3.4.3 Italy
  3.4.4 Spain
  3.4.5 Poland
  3.4.6 Belgium
3.5 Australia
3.6 China
3.7 Japan
3.8 South Korea
3.9 India

4. GLOBAL BREAST CANCER IMMUNOTHERAPY APPROVED DRUGS SALES, PRICE, DOSAGE & PATENT ANALYSIS

4.1 Keytruda (Pembrolizumab)
4.2 Perjeta (Pertuzumab)
4.3 Kadcyla (Ado-Trastuzumab Emtansine)
4.4 Phesgo (pertuzumab trastuzumab hyaluronidase)
4.5 Trodelvy (Sacituzumab Govitecan)
4.6 Herceptin (Trastuzumab)
4.7 Enhertu (Fam-Trastuzumab Deruxtecan)
4.8 Margenza (Margetuximab)
4.9 Tecentriq (Atezolizumab)
4.10 Avastin (Bevacizumab)

5. GLOBAL BREAST CANCER IMMUNOTHERAPIES CLINICAL TRIALS INSIGHT

5.1 By Biomarker
5.2 By Company
5.3 By Country
5.4 By Patient Segment
5.5 By Phase

6. GLOBAL BREAST CANCER IMMUNOTHERAPIES CLINICAL TRIALS BY COMPANY, COUNTRY & INDICATION

6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered

7. MARKETED BREAST CANCER IMMUNOTHERAPIES CLINICAL INSIGHT

8. THERAPEUTIC APPROACHES TO BREAST CANCER IMMUNOTHERAPY

8.1 Monotherapeutic Approaches
8.2 Combination Therapy Approach
  8.2.1 Combination Of Targeted Therapy & Endocrine Therapy
  8.2.2 Combination With Immunotherapy
  8.2.3 Combination Strategies That Include Triple Agents

9. NEW IMMUNOTHERAPEUTIC APPROACHES IN TRIALS FOR BREAST CANCER TREATMENT

9.1 Emerging Molecular Targets For CAR T Cell Immunotherapy
9.2 Bispecific Antibodies
9.3 Vaccine Based Therapy
9.4 Oncolytic Viruses
9.5 Immunotherapy with Tumor Infiltrating Lymphocytes (TILs)
9.6 Cytokine Therapy

10. GLOBAL BREAST CANCER IMMUNOTHERAPY MARKET DYNAMICS

10.1 Market Drivers
10.2 Market Challenges

11. COMPETITIVE LANDSCAPE

11.1 Amgen
11.2 Antibody Therapeutics
11.3 AstraZeneca
11.4 Biocad
11.5 Bristol-Myers Squibb
11.6 EirGenix
11.7 EpiThany
11.8 Genentech
11.9 ImmunityBio
11.10 LeadArtis
11.11 Mayo Clinic
11.12 Merck
11.13 Novartis
11.14 PACT Pharma
11.15 Pfizer
11.16 Prestige BioPharma
11.17 Protheragen
11.18 Roche
11.19 Samsung Bioepis
11.20 Shanghai Novamab Biopharmaceuticals
11.21 Therabest Korea
11.22 Xuanzhu Biopharmaceutical

List Of Figures

LIST OF FIGURES

Figure 1-1: Conventional Treatment Strategies Used for Breast Cancer
Figure 1-2: Classification of Immunotherapy
Figure 1-3: Different Immunotherapeutic Approaches
Figure 1-4: Majorly used current biomarkers for Breast Cancer
Figure 1-5: Emerging and Novel Biomarkers for Breast Cancer
Figure 2-1: Global – Breast Cancer immunotherapy Market Sales (US$ Billion), 2019 – 2023
Figure 2-2: Global – Breast Cancer immunotherapy Market Quarterly Sales (US$ Billion)’ 2022
Figure 2-3: Global – Breast Cancer immunotherapy Market By Drug (US$ Million), Q1’2023
Figure 2-4: Global – Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
Figure 2-5: US – Breast Cancer immunotherapy Market (US$ Billion)’ 2019 - 2023
Figure 2-6: US – Breast Cancer immunotherapy Market By Drug (US$ Million), Q1’2023
Figure 2-7: US – Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
Figure 2-8: Europe – Breast Cancer immunotherapy Market (US$ Million)’ 2019 – 2023
Figure 2-9: Europe – Breast Cancer immunotherapy Market By Drug (US$ Million), Q1’2023
Figure 2-10: Europe – Breast Cancer immunotherapy Market By Drug (US$ Million), 2022
Figure 2-11: Global – Breast Cancer immunotherapy Market Sales (US$ Billion), 2023 - 2028
Figure 3-1: US – Share of Breast Cancer Cases In Total Cancer Cases, 2022
Figure 3-2: US – Reimbursement System
Figure 3-3: UK – Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-4: UK – Key Reimbursement Stakeholders
Figure 3-5: Canada – Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-6: Canada – Drug Reimbursement Process
Figure 3-7: Europe – Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-8: Germany – Reimbursement Of Drugs
Figure 3-9: France – Drug Pricing and Reimbursement Process
Figure 3-10: Italy – Drug Pricing and Reimbursement Process
Figure 3-11: Spain – Pricing & Reimbursement Process
Figure 3-12: Poland – Stages Of Reimbursement Decision Making Process
Figure 3-13: Australia – Drug Payment Process
Figure 3-14: China – Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-15: China – Negotiation Process for National Reimbursement Drug List (NRLD)
Figure 3-16: Japan – Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-17: Japan – Reimbursement Process For Public Insured Medical Services
Figure 3-18: South Korea – Share of Breast Cancer Cases In Total Cancer Cases, 2020
Figure 3-19: South Korea – Flow Of Reimbursement Decision making For New Drug
Figure 4-1: Global – Keytruda Annual Sales (US$ Million), 2019 – 2023
Figure 4-2: Global – Keytruda Quarterly Sales (US$ Million), 2022
Figure 4-3: US – Keytruda Annual Sales (US$ Million), 2019 – 2023
Figure 4-4: US – Keytruda Quarterly Sales (US$ Million), 2022
Figure 4-5: US - Keytruda Price per Unit & per Vial for 25mg/mL Intravenous Solution (US$), May’2023
Figure 4-6: Keytruda – List Price of a Supply for 3 & 6 Weeks (US$), May’2023
Figure 4-7: Keytruda – Cost of Treatment for Different Administration Schedules, May’2023
Figure 4-8: UK - Keytruda Price per 100mg/4mL Intravenous Solution, May’2023
Figure 4-9: Keytruda – Patent Expiration Year
Figure 4-10: Global – Perjeta Annual Sales (US$ Million), 2019 – 2023
Figure 4-11: Global – Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-12: US – Perjeta Annual Sales (US$ Million), 2019 – 2023
Figure 4-13: US – Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-14: Europe – Perjeta Annual Sales (US$ Million), 2019 – 2023
Figure 4-15: Europe – Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-16: Japan – Perjeta Annual Sales (US$ Million), 2019 – 2023
Figure 4-17: Japan – Perjeta Quarterly Sales (US$ Million), 2022
Figure 4-18: US – Perjeta per Unit & Price for 420mg/14mL Intravenous Solution (US$), May’2023
Figure 4-19: Perjeta – Total Cost Of Treatment Cycle (US$), May’2023
Figure 4-20: UK – Perjeta Price per Vial of 420mg/14mL, May’2023
Figure 4-21: Perjeta – Patent Filing Year v/s Expiration Year – US, Canada & Australia
Figure 4-22: Global – Kadcyla Annual Sales (US$ Million), 2019 – 2023
Figure 4-23: Global – Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-24: US – Kadcyla Annual Sales (US$ Million), 2019 – 2023
Figure 4-25: US – Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-26: Europe – Kadcyla Annual Sales (US$ Million), 2019 – 2023
Figure 4-27: Europe – Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-28: Japan – Kadcyla Annual Sales (US$ Million), 2019 – 2023
Figure 4-29: Japan – Kadcyla Quarterly Sales (US$ Million), 2022
Figure 4-30: US – Kadcyla per Unit & Price (US$) For 1 Powder Injection, May’2023
Figure 4-31: Kadcyla – Cost of Treatment for 100mg & 160mg of Intravenous Powder, May’2023
Figure 4-32: UK - Kadcyla Price per 180mg & 160mg Vial, May’2023
Figure 4-33: Kadcyla – Patent Expiration Year – US v/s UK
Figure 4-34: Global – Phesgo Annual Sales (US$ Million), 2020 – 2023
Figure 4-35: Global – Phesgo Quarterly Sales (US$ Million), 2022
Figure 4-36: US – Phesgo Annual Sales (US$ Million), 2019 – 2023
Figure 4-37: US – Phesgo Quarterly Sales (US$ Million), 2022
Figure 4-38: Europe – Phesgo Annual Sales (US$ Million), 2019 – 2023
Figure 4-39: Europe – Phesgo Quarterly Sales (US$ Million), 2022
Figure 4-40: US – Phesgo Price per Unit for 10mL of 20,000 Units Phesgo Subcutaneous Injection (US$), May’2023
Figure 4-41: US – Phesgo Price per Unit for 15mL of 30,000 Units Phesgo Subcutaneous Injection (US$), May’2023
Figure 4-42: Phesgo – Cost of Treatment Cycle (US$), May’2023
Figure 4-43: UK – Phesgo Price per Unit for 10mL of 600mg/600mg Phesgo Subcutaneous Injection, May’2023
Figure 4-44: UK – Phesgo Price per Unit for 15mL of 1200mg/600mg Phesgo Subcutaneous Injection, May’2023
Figure 4-45: Phesgo – Patent Approval & Expiration Year
Figure 4-46: Global – Trodelvy Annual Sales (US$ Million), 2021 - 2023
Figure 4-47: Global – Trodelvy Quarterly Sales (US$ Million), 2022
Figure 4-48: US – Trodelvy Annual Sales (US$ Million), 2021 –2023
Figure 4-49: US – Trodelvy Quarterly Sales (US$ Millions), 2022
Figure 4-50: Europe – Trodelvy Annual Sales (US$ Million), 2021 – 2023
Figure 4-51: Europe – Trodelvy Quarterly Sales (US$ Millions), 2022
Figure 4-52: Trodelvy - Per Unit & Price for 180mg of Intravenous Powder (US$), May’2023
Figure 4-53: Trodelvy – Cost of Treatment Cycle (US$), May’2023
Figure 4-54: UK - Trodelvy Price per 180mg Vial Powder, May’2023
Figure 4-55: Trodelvy – US v/s UK Patent Expiration Year
Figure 4-56: Global – Herceptin Annual Sales (US$ Million), 2019 – 2023
Figure 4-57: Global – Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-58: US – Herceptin Annual Sales (US$ Millions), 2019 – 2023
Figure 4-59: US – Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-60: Europe – Herceptin Annual Sales (US$ Million), 2019 – 2023
Figure 4-61: Europe - Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-62: Japan – Herceptin Annual Sales (US$ Million), 2019 - 2023
Figure 4-63: Japan – Herceptin Quarterly Sales (US$ Million), 2022
Figure 4-64: US – Herceptin per Unit & Price for 150mg Intravenous Powder For Injection (US$)
Figure 4-65: Herceptin – Cost of Treatment (Schedule 1) (US$), May’2023
Figure 4-66: Herceptin – Cost of Treatment (Schedule 1) (US$), May’2023
Figure 4-67: Herceptin – Cost of Treatment for Metastatic HER2 Overexpressing Breast Cancer (US$), May’2023
Figure 4-68: UK – Herceptin Price per Vial for 150mg Powder, May’2023
Figure 4-69: Herceptin - Patent Filing Year v/s Expiration Year – US & Canada
Figure 4-70: Global – Enhertu Annual Sales (US$ Million), 2020 – 2023
Figure 4-71: Global – Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-72: US – Enhertu Annual Sales (US$ Million), 2020 – 2023
Figure 4-73: US – Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-74: EU – Enhertu Annual Sales (US$ Million), 2020 – 2023
Figure 4-75: EU – Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-76: Japan – Enhertu Annual Sales (US$ Million), 2020 – 2023
Figure 4-77: Japan – Enhertu Quarterly Sales (US$ Million), 2022
Figure 4-78: US - Enhertu per Unit & Price for 100 mg Of Intravenous Powder (US$)
Figure 4-79: UK– Enhertu Price per 100mg Powder, May’2023
Figure 4-80: Enhertu – Cost of Treatment With 100mg intravenous Powder, May’2023
Figure 4-81: Margenza – Research & Development Annual Expense (US$ Million), 2020 - 2022
Figure 4-82: Margenza –Research & Development Quarterly Expense (US$ Million), 2022
Figure 4-83: US - Margenza Price per Unit for 25mg/mL Intravenous Solution (US$), May’2023
Figure 4-84: Margenza – Cost of Treatment with Different Volumes of Intravenous Solution, May’2023
Figure 4-85: Global – Tecentriq Annual Sales (US$ Million), 2019 – 2023
Figure 4-86: Global – Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-87: US – Tecentriq Annual Sales (US$ Million), 2019 – 2023
Figure 4-88: US – Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-89: Europe– Tecentriq Annual Sales (US$ Million), 2019 – 2023
Figure 4-90: Europe – Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-91: Japan – Tecentriq Annual Sales (US$ Million), 2019 – 2023
Figure 4-92: Japan – Tecentriq Quarterly Sales (US$ Million), 2022
Figure 4-93: US - Tecentriq Price per Unit for 840mg/14mL & 1200mg/20mL of Intravenous Solution (US$), May’2023
Figure 4-94: UK – Tecentriq Price per Unit for 840mg/14mL & 1200mg/20mL of Intravenous Solution, May’2023
Figure 4-95: Tecentriq – Global Patent Approval & Expiration Year
Figure 4-96: Global – Avastin Annual Sales (US$ Million), 2019 – 2023
Figure 4-97: Global - Avastin Quarterly Sales (US$ Million), 2022
Figure 4-98: US – Avastin Annual Sales (US$ Million), 2019 – 2023
Figure 4-99: US– Avastin Quarterly Sales (US$ Million), 2022
Figure 4-100: Europe – Avastin Annual Sales (US$ Million), 2019 – 2023
Figure 4-101: Europe – Avastin Quarterly Sales (US$ Million), 2022
Figure 4-102: Japan – Avastin Annual Sales (US$ Million), 2019 -2023
Figure 4-103: Japan – Avastin Quarterly Sales (US$ Million), 2022
Figure 4-104: US - Avastin Price per Unit for 25mg/mL of Intravenous Solution (US$), May’2023
Figure 4-105: UK – Avastin Price per Unit for Different Concentrations of Infusion Vial, May’2023